Document is current

Article History

Received: 28 September 2023

Accepted: 8 November 2023

First Online: 21 November 2023

Declarations

:

: Not applicable.

: All authors have consented to publication

: J.B., is a Founder and Director of CDI Labs, Inc., a Founder of and consultant to Neochromosome, Inc, a Founder, SAB member of and consultant to ReOpen Diagnostics, LLC and serves or served on the Scientific Advisory Board of the following: Logomix, Inc., Modern Meadow, Inc., Rome Therapeutics, Inc., Sample6, Inc., Sangamo, Inc., Tessera Therapeutics, Inc. and the Wyss Institute. K.B., interests are managed by Dana-Farber Cancer Institute K.C., Consultant, Rome Therapeutics. M.C., Employee at Pfizer Center for Therapeutic Innovation and may own Pfizer stock. J.C., Member of the scientific advisory board, Rome Therapeutics D.D.D.C., received research funds from Pfizer and Nektar Therapeutics. He is a co-founder and shareholder of DNAMx, Inc .J.D., Employee and owner of share options in Enara Bio B.G., has received honoraria for speaking engagements from Merck, Bristol Meyers Squibb, and Chugai Pharmaceuticals; has received research funding from Bristol Meyers Squibb and Merck; and has been a compensated consultant for Darwin Health, Merck, PMV Pharma and Rome Therapeutics of which he is a co-founder. G.K., is a scientific co-founder of Enara Bio and a member of its scientific advisory board. He has consulted for EnaraBio and Repertoire Immune Medicines S.K., Employee and owner of share options in Rome TherapeuticsA.L., PMV Pharma and Chugai Pharmaceuticals A.N., has a joint patent with GeNeuro on a monoclonal antibody to HML-2 S.P., Employee and owner of share options in Enara BioD.R., Employee of Paragon Therapeutics J.M.S., is a cofounder and SAB chair of Transposon Therapeutics, Inc. and consults for Atropos Therapeutics, Inc., Gilead Sciences, Inc. and Oncolinea Inc. D.T.T., is a founder, consultant, and has equity in ROME Therapeutics. He has received consulting fees from Sonata Therapeutics and Tekla Capital, is a founder and has equity in PanTher Therapeutics and TellBio, Inc., is on the advisory board for Improve Bio, Inc., has received honorariums from Moderna and Ikena Oncology, receives research support from ACD-Biotechne, AVA LifeScience GmbH, and Incyte Pharmaceuticals, which are not related to this work. His interests were reviewed and are managed by Massachusetts General Hospital and Mass General Brigham in accordance with their conflict of interest policies.